The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Diagnostic and clinical impact of the revised definition of light chain MGUS
In this video, Victor Jimenez Zepeda, MD, PhD, University of Calgary, Calgary, Canada, discusses the revised definition of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) and its impact on diagnoses in the clinic. When using the revised definition of LC-MGUS in their patients, the amount of false positives was reduced, which also reduced the burden of patients needing to see a hematologist as opposed to a general practitioner. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
